Ajovy was designed to do one thing precisely: find CGRP molecules in your bloodstream and neutralize them before they can trigger pain signaling. It is an engineered antibody built specifically for migraine prevention, not repurposed from another condition.
For people whose migraines are heavily driven by CGRP, Ajovy can be life-changing. But for roughly half of patients in clinical trials, even sustained CGRP neutralization didn't meaningfully reduce migraine days. That number isn't a flaw in the drug - it reflects the reality that many migraines run through pathways CGRP doesn't control.
If Ajovy isn't working for you, the question isn't whether the drug is doing its job. It almost certainly is. The question is whether CGRP is the right target for your particular migraine pattern.
Key distinction
Ajovy intercepts the CGRP molecule itself, while Aimovig blocks the receptor CGRP binds to. Think of it this way - Ajovy catches the ball mid-air, Aimovig covers the goal. Same sport, different defensive strategy. This difference matters when deciding whether switching between them is worth trying.
How Ajovy Works - and Where It Can't Reach
Fremanezumab is a monoclonal antibody that binds directly to CGRP molecules circulating in your blood and tissues. Once bound, the CGRP molecule is neutralized - it can't attach to any receptor or trigger the vasodilation and inflammatory cascade associated with migraine pain.
This approach has a clear strength: it removes CGRP from the equation entirely, regardless of which receptor subtype it would have activated. But it also has clear limits:
It only works on peripheral CGRP. Ajovy is a large protein molecule that doesn't easily cross the blood-brain barrier. It primarily neutralizes CGRP in the trigeminovascular system and meningeal vessels - not in the brainstem or cortex where centralized migraine processing happens.
It can't address non-CGRP pain pathways. If your migraines are driven by histamine release, hormonal fluctuations, or autonomic dysfunction, removing CGRP from the system is like fixing one leak while the main pipe is still broken.
It has no effect on central sensitization. In long-standing chronic migraine, pain processing can become self-sustaining in the brainstem. Peripheral CGRP neutralization may not reach these centrally driven patterns.
None of this means Ajovy is a weak drug. It does exactly what it was designed to do. The question is whether what it does is what your migraines need.
Quarterly vs Monthly Dosing: Why Schedule Matters
Ajovy is unique among CGRP antibodies in offering two dosing options. This flexibility is an advantage, but the two schedules are not pharmacologically identical:
Monthly - 225mg
One subcutaneous injection every 4 weeks. Drug levels rise, plateau, and begin to taper before the next dose - but the trough is relatively shallow.
Result: More stable drug levels throughout the month. Less variation between peak and trough.
Quarterly - 675mg
Three injections (675mg total) every 12 weeks. Drug levels spike higher initially, then gradually decline over three months before the next dose.
Result: Greater convenience, but wider swings between peak and trough levels. Some patients notice reduced protection in weeks 10-12.
If you are on the quarterly schedule and notice your migraines returning or worsening in the final weeks before your next dose, this is a pharmacokinetic signal - not treatment failure. Switching to the monthly 225mg schedule may provide more consistent coverage. This is worth discussing with your clinician before concluding the drug doesn't work.
When Ajovy Worked and Then Stopped
1. Your migraine layers shifted
Migraine is not a single-pathway disease. Most people have multiple contributing layers - CGRP, histamine, hormones, sleep quality, autonomic tone, stress. Ajovy suppresses the CGRP layer. If that layer was dominant when you started treatment, the drug worked well.
But if other layers have since increased - perimenopause began, seasonal allergies worsened, sleep deteriorated, or a new stressor appeared - those layers can push you past your migraine threshold even with CGRP fully suppressed. The antibody is still working. The system around it changed.
2. Seasonal and environmental shifts
Barometric pressure changes, temperature swings, pollen seasons, and shifts in daylight hours can all activate migraine pathways that CGRP blockade doesn't cover. A patient who started Ajovy in winter and experienced great results may find it "stops working" in spring - not because of the drug, but because environmental triggers are now adding load to a system that CGRP suppression alone can no longer hold below threshold.
3. Hormonal transitions
Estrogen fluctuations are one of the most powerful migraine drivers, and they change over time. Perimenopause introduces more volatile estrogen swings. New contraceptives alter hormonal baselines. Pregnancy and postpartum shift the entire hormonal landscape. If Ajovy worked during a hormonally stable period and stopped working during a transition, the hormonal layer likely overtook the CGRP layer as the dominant driver.
4. Medication overuse complicating the picture
If acute medication use has increased while on Ajovy, medication overuse headache can develop on top of the migraine pattern. CGRP antibodies don't prevent rebound headache from frequent triptan or analgesic use. The Ajovy is still suppressing CGRP-mediated attacks, but a new layer of medication-induced headache has been added to the system.
Switching CGRP Antibodies: Molecule Blockers vs Receptor Blockers
If Ajovy isn't working, one option worth discussing with your clinician is switching to Aimovig (erenumab), which blocks the CGRP receptor rather than the molecule. These are genuinely different mechanisms:
Molecule blockers
Ajovy & Emgality
Neutralize CGRP itself. All free CGRP molecules are potential targets. But some CGRP may still reach receptors if antibody saturation isn't complete.
Receptor blocker
Aimovig
Blocks the CGRP receptor directly. CGRP still circulates freely, but it can't activate its primary receptor. May affect receptor subtypes differently than molecule capture.
Published case series and clinical experience suggest that some patients who fail one mechanism do respond to the other. The response rates for switching aren't dramatic, but they're real enough that most headache specialists consider it a reasonable step before abandoning the CGRP class entirely.
Switching from Ajovy to Emgality (both molecule blockers) is less likely to produce a different result, since the mechanism is essentially the same. The more informative switch is between a molecule blocker and the receptor blocker.
If you've tried both approaches - molecule blocker and receptor blocker - and neither helped, that's a strong signal that CGRP isn't your dominant migraine driver. You can also consider whether Nurtec (rimegepant), a small-molecule gepant that crosses the blood-brain barrier more readily, might reach central CGRP pathways the antibodies can't access.
When Ajovy Does Work
Understanding who responds well to Ajovy helps clarify why non-response happens. Ajovy tends to work best when the migraine pattern has strong CGRP-driven characteristics:
- • Triptans work well acutely. Triptans and CGRP antibodies both target the trigeminovascular system. If triptans reliably abort your attacks, it suggests strong serotonin/CGRP overlap - the pathway Ajovy was designed to suppress.
- • Classic aura patterns. Cortical spreading depression that produces visual aura triggers a wave of CGRP release. Migraines that consistently involve aura may have a stronger CGRP component.
- • Purely vascular presentation. Throbbing, pulsating pain that worsens with physical activity and responds to cold application suggests vascular-mediated pain - the type CGRP-driven vasodilation produces.
- • Episodic rather than chronic pattern. Patients with episodic migraine (fewer than 15 headache days per month) tend to respond better to CGRP antibodies than patients with long-standing chronic migraine, likely because chronic patterns involve more central sensitization.
- • Limited comorbidities. People without significant autonomic dysfunction, mast cell issues, or hormonal instability are more likely to have CGRP as a primary driver rather than one of several competing mechanisms.
If your migraine pattern doesn't fit these characteristics, it doesn't mean the drug can't help - but it reduces the probability that CGRP is your dominant pathway.
What to Discuss With Your Clinician
- • Whether switching from quarterly to monthly dosing could provide more stable coverage before concluding the drug doesn't work
- • Whether trying a receptor blocker (Aimovig) makes sense if Ajovy as a molecule blocker hasn't been effective
- • Whether a gepant like Nurtec could reach central CGRP pathways the antibodies miss
- • Whether lifestyle layers - sleep, sodium, hydration, stress management - could reduce the non-CGRP load enough for Ajovy to become effective again
- • Whether other medication failures together with Ajovy's failure help narrow down the actual dominant pathway
The Part Most People Miss
Ajovy failing isn't just a disappointment - it's a diagnostic signal. You now know that sustained, round-the-clock CGRP neutralization is not enough to control your migraines. That eliminates an entire category of migraine mechanism and points the investigation somewhere more specific.
Each treatment you've tried that hasn't worked narrows the search. Propranolol failed? Adrenergic instability may not be central. Botox failed? Peripheral nerve signaling isn't the main input. Ajovy failed? CGRP isn't running the show. Rather than seeing these as dead ends, think of them as narrowing a map. The answer is still out there - you're just crossing off the wrong addresses.
This guide is for education and pattern-recognition only. It is not medical advice and is not a plan to start, stop, or change any medication, supplement, or test. Always discuss treatment decisions with a licensed clinician who knows your history.
Clinical and Review Articles
- Silberstein SD et al. Fremanezumab for the preventive treatment of chronic migraine. New England Journal of Medicine. 2017;377(22):2113-2122.
- Dodick DW et al. Effect of fremanezumab compared with placebo for prevention of episodic migraine: a randomized clinical trial. JAMA. 2018;319(19):1999-2008.
- Goadsby PJ et al. A controlled trial of erenumab for episodic migraine. New England Journal of Medicine. 2017;377(22):2123-2132.
- Edvinsson L. The trigeminovascular pathway: role of CGRP and CGRP receptors in migraine. Headache. 2017;57(S2):47-55.
- Raffaelli B et al. Switching from one monoclonal antibody targeting CGRP or its receptor to another in migraine prevention: a systematic review. Cephalalgia. 2022;42(11-12):1193-1202.
Already have test results?
If you've accumulated years of normal tests but still have migraines, those records may contain patterns that haven't been examined together.
Related reading
This is educational content, not medical advice. Always consult a qualified clinician.